Broad syntheses related to this topic

loading
2 References (2 articles) loading Revert Studify

Broad synthesis

Unclassified

Irritable bowel syndrome.

Auteurs Ford AC , Talley NJ
Journal BMJ (Clinical research ed.)
Year 2012
Liens Pubmed

Cet article inclut 13 Systematic reviews Systematic reviews (13 references) 16 Primary studies Primary studies (16 references)

Loading references information

Broad synthesis

Unclassified

Irritable bowel syndrome.

Auteurs Ford AC , Vandvik PO
Journal Clinical evidence
Year 2010
Liens Pubmed PubMed Central

Cet article inclut 11 Primary studies Primary studies (11 references) 8 Systematic reviews Systematic reviews (8 references)

Loading references information
INTRODUCTION: The prevalence of irritable bowel syndrome (IBS) varies depending on the criteria used to diagnose it, but it ranges from about 5% to 20%. IBS is associated with abnormal gastrointestinal motor function and enhanced visceral perception, as well as psychosocial and genetic factors. People with IBS often have other bodily and psychiatric symptoms, and have an increased likelihood of having unnecessary surgery compared with people without IBS. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments in people with IBS? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 18 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: 5HT(3) receptor antagonists (alosetron and ramosetron); 5HT(4) receptor agonists (tegaserod); antidepressants (tricyclic antidepressants and selective serotonin reuptake inhibitors [SSRIs]); antispasmodics (including peppermint oil); cognitive behavioural therapy (CBT); hypnotherapy; soluble and insoluble fibre supplementation; and loperamide.